Fidelity International’s Acceleron Pharma XLRN Stock Holding History

Fidelity International’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-124	Closed	-$7K	–	1045
2019 Q4	$7K	Buy	+124	New	+$5.65K	﹤0.01%	762
2018 Q3	–	Sell	-432,828	Closed	-$21M	–	1007
2018 Q2	$21M	Buy	+432,828	New	+$15.8M	0.03%	383

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Fidelity International's XLRN Position: Q1 2020 in Review

Fidelity International sold out of Acceleron Pharma (XLRN) in Q1 2020, closing a stake of 124 shares — an estimated $7K sold.

Fidelity International first reported a position in XLRN in Q2 2018 and held it in 2 quarters. The position peaked at $21M in Q2 2018. 217 funds tracked by Wall St. Rank hold XLRN as of Q1 2020.

Fidelity International reported no remaining Acceleron Pharma position as of Q1 2020 after selling out during the quarter.
Fidelity International sold 124 Acceleron Pharma shares in Q1 2020, an estimated $7K.
Fidelity International first reported a position in Acceleron Pharma in Q2 2018 and held it in 2 quarters.
Fidelity International's Acceleron Pharma position peaked at $21M in Q2 2018.
217 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2020.

Based on Fidelity International's 13F filing for Q1 2020, filed 14 May 2020.